Endoscopic pancreaticobiliary drainage with overlength stents to prevent delayed perforation after endoscopic papillectomy: A pilot study

Table 1 Baseline characteristics of the patients with lesions of the major duodenal papilla

No.	Sex	Age (yr)	Clinical presentation	Tumor size (mm)	Biopsy pathology
1	M	58	Abdominal pain	20	Adenomatoid hyperplasia/LGD
2	M	73	Incidental finding	17	Tubular adenoma
3	M	50	Incidental finding	25	Adenomatoid hyperplasia
4	M	79	Incidental finding	35	Inflammation/adenomatoid hyperplasia
5	M	56	Abdominal pain	15	Inflammation/HGD/field cancerization?

M: Male; LGD: Low-grade dysplasia; HGD: High-grade dysplasia.

Table 2 Technical results and patient outcomes

No.	Tumor size (mm)	Submucosal injection	Resection	Length of biliary stent T/D (mm)	Length of pancreatic stents T/D (mm)	Operative time (min)	Complications	Additional therapy	Recurrence	Follow-up (mo)
1	20	(-)	En bloc	35/13	35/12	61	(-)	PPPD	(-)	17
2	17	(+)	En bloc	35/13	35/12	55	Panceatitis	(-)	(-)	15
3	25	(-)	Two Pieces	35/14	35/12	63	(-)	(-)	(-)	12
4	35	(-)	En bloc	33/14	30/12	70	(-)	(-)	(-)	8
5	15	(-)	En bloc	38/13	35/11	66	(-)	(-)	(-)	8

T/D: Total length/length of the duct segment; PPPD: Pylorus-preserving pancreaticoduodenectomy; M: Male; LGD: Low-grade dysplasia; HGD: High-grade dysplasia.

Table 3 Biopsy diagnosis and final diagnosis

No.	Tumor size (mm)	Biopsy pathology	Final pathology	Depth of invasion	Mucosal margin	Deep margin
1	20	Adenomatoid hyperplasia/LGD	Adenocarcinoma/poorly differentiated	Muscularis propria	(-)	(+)
2	17	Tubular adenoma	Tubular adenoma/HGD	Mucosa	(-)	(-)
3	25	Adenomatoid hyperplasia	Tubulovillous adenoma/HGD	Mucosa	(-)	(-)
4	35	Inflammation/adenomatoid hyperplasia	Hamartomatous polyp/LGD	Mucosa	(-)	(-)
5	15	Inflammation/HGD/field cancerization?	Atypical juvenile polyposis/tubulovillous adenoma/HGD/field cancerization	Muscularis mucosae and submucosa	(-)	(-)

LGD: Low-grade dysplasia; HGD: High-grade dysplasia.